Discordance between Liver Biopsy and FibroScan® in Assessing Liver Fibrosis in Chronic Hepatitis B: Risk Factors and Influence of Necroinflammation by Kim, Seung Up et al.
Discordance between Liver Biopsy and FibroScanH in
Assessing Liver Fibrosis in Chronic Hepatitis B: Risk
Factors and Influence of Necroinflammation
Seung Up Kim
1,2,5, Ja Kyung Kim
1,2,5, Young Nyun Park
3,4,5,6*, Kwang-Hyub Han
1,2,5,6*
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul,
Korea, 3Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, 4Center for Chronic Metabolic Disease, Yonsei University College of Medicine,
Seoul, Korea, 5Liver Cirrhosis Clinical Research Center, Seoul, Korea, 6Brain Korea 21 Project for Medical Science, Seoul, Korea
Abstract
Background: Few studies have investigated predictors of discordance between liver biopsy (LB) and liver stiffness
measurement (LSM) using FibroScanH. We assessed predictors of discordance between LB and LSM in chronic hepatitis B
(CHB) and investigated the effects of necroinflammatory activity.
Methods: In total, 150 patients (107 men, 43 women) were prospectively enrolled. Only LSM with $10 valid measurements
was considered reliable. Liver fibrosis was evaluated using the Laennec system. LB specimens ,15 mm in length were
considered ineligible. Reference cutoff LSM values to determine discordance were calculated from our cohort (6.0 kPa for
$F2, 7.5 kPa for $F3, and 9.4 kPa for F4).
Results: A discordance, defined as a discordance of at least two stages between LB and LSM, was identified in 21 (14.0%)
patients. In multivariate analyses, fibrosis stages F3–4 and F4 showed independent negative associations with discordance
(P=0.002; hazard ratio [HR], 0.073; 95% confidence interval [CI], 0.014–0.390 for F3–4 and P=0.014; HR, 0.067; 95% CI,
0.008–0.574 for F4). LSM values were not significantly different between maximal activity grades 1–2 and 3–4 in F1 and F2
fibrosis stages, whereas LSM values were significantly higher in maximal activity grade 3–4 than 1–2 in F3 and F4 fibrosis
stage (median 8.6 vs. 11.3 kPa in F3, P=0.049; median 11.9 vs. 19.2 kPa in F4, P=0.009).
Conclusion: Advanced fibrosis stage (F3–4) or cirrhosis (F4) showed a negative correlation with discordance between LB
and LSM in patients with CHB, and maximal activity grade 3–4 significantly influenced LSM values in F3 and F4.
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Introduction
Because the prognosis of and management strategies for patients
with chronic liver diseases depend strongly on the severity of liver
fibrosis, early detection of significant fibrosis is key [1]. To date,
liver biopsy (LB) has been the gold standard for assessing liver
fibrosis. However, its invasiveness, potential adverse events [2],
sampling errors [3], and interpretational variability [4] have
encouraged clinicians to seek more accurate and noninvasive tools
for assessing liver fibrosis.
Recently, liver stiffness measurement (LSM) using FibroScanH
was introduced as a noninvasive device to accurately assess liver
fibrosis [5]. In view of the results achieved so far, LSM can help
physicians decide treatment strategies, predict prognosis, and
monitor disease progression or regression in patients with chronic
liver disease. Despite the clinical usefulness of LSM, several
confounding factors that can diminish the accuracy of LSM have
been identified, such as necroinflammatory activity, reflected by a
high alanine aminotransferase (ALT) level, cholestasis, or heart
failure [6–12]. In addition to these extrinsic factors, LSM should
satisfy the intrinsic prerequisites for preserving the validity of LSM:
$10 valid measurements, a success rate $60%, and an
interquartile range (IQR)/median LSM value among valid
measurements (IQR/M) ,0.3. However, because these criteria
are not based on scientific evidence, several studies have tried to
demonstrate the clinical relevance of these criteria by identifying
factors that predict discordant results between LB and LSM in
estimating liver fibrosis. Results from these studies have identified
elevated ALT, high IQR/M, high body mass index (BMI), and
fibrosis stage at the time of LB as predictors of discordance [13–
15]. Although elevated ALT has been considered to be the single
most important confounder on LSM, the effects of necroinflam-
matory activity, which is closely related to ALT level, on
discordance between LB and LSM have not been determined.
Thus, in this study, we examined predictors of discordance
between LB and LSM in patients with chronic hepatitis B
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32233(CHB) and investigated the effects of necroinflammatory activity
on LSM.
Methods
Patients
Between January 2007 and December 2009, 196 consecutive
patients with CHB, defined by detectable hepatitis B virus surface
antigen (HBsAg) for more than 6 months and positive hepatitis B
virus (HBV) DNA by polymerase chain reaction assay, underwent
both LB and LSM before starting antiviral treatment. Of them,
184 (93.9%) patients received LSMs on the same day as LB. The
remaining LSMs were conducted at a median of 6 (range, 1–24)
days before LB in 12 (6.1%) patients.
No patient had evidence of decompensated liver cirrhosis, such as
a history of variceal bleeding, ascitic decompensation, hepatic
encephalopathy, or Child-Pugh class B or C at the time of LB and
LSM. Exclusions criteria were as follows: (1) previous antiviral
treatment before LB, (2) evidence of liver cancer or another
malignancy, (3) coinfection wtih hepatitis C virus, hepatitis D virus,
orhumanimmunodeficiencyvirus,(4)alcoholconsumptioninexcess
of 40 g/day for more than 5 years, (5) LB specimens shorter than
15 mm in length or unknown LB length, (6) right-sided heart failure,
(7) LSM failure, or (8) unrelaible LSM (,10 valid measurments).
This study cohort includes a subset of a previous multicenter
Korean study [14]. The study protocol was consistent with the
ethical guidelines of the 1975 Declaration of Helsinki. Written
informed consent was obtained from each participant or
responsible family members after the possible complications of
LB had been fully explained. This study was approved by the
independent institutional review boards of Severance Hospital,
Yonsei University College of Medicine.
Clinical data
Demographic details and BMI were collected. The following
laboratoryparameterswerealso collectedfromallthepatientsatthe
time of LSM; ALT, gamma-glutamyltranspeptidase (GGT), and
platelet count. HBsAg was measured using standard enzyme-linked
immunosorbent assays (Abbott Diagnostics, Abbott Park, IL, USA).
The upper limit of normal (ULN) for ALT was defined as 40 IU/L.
Liver stiffness measurement
LSM was obtained according to the instructions provided by the
manufacturer. Details of the technical background and examina-
tion procedure have been described previously [5,16–18]. The
success rate was calculated as the number of valid measurements
divided by the total number of measurements. Results are
expressed in kilopascals (kPa). IQR was defined as an index of
LSM intrinsic variability corresponding to the 25
th and 75
th
percentiles intervals around the LSM result containing 50% of the
valid measurements. The median value was considered represen-
tative of the elastic modulus of the liver. Only procedures with
$10 validated measurements were considered reliable, regardless
of success rate and IQR/M. The same experienced operator
(.3,000 LSM examinations), blinded to LB results and the clinical
data of the study population performed all LSM examinations.
Liver biopsy and histological evaluation
LB specimens were fixed in formalin and embedded in paraffin.
Sections (4 mm) were stained with hematoxylin and eosin and
Masson’s trichrome. All liver tissue samples were evaluated by an
experienced hepatopathologist (YN Park) who was blinded to the
clinical data of study population, including LSM results. Liver fibrosis
and necroinflammation were evaluated semiquantitatively according
to the Laennec system [19]. Fibrosis was scored in five grades at first:
0, no definite fibrosis, 1, minimal fibrosis (no septa or rare thin
septum; may have portal expansion or mild sinusoidal fibrosis), 2,
mild fibrosis (occasional thin septa), 3, moderate fibrosis (moderate
thin septa; up to incomplete cirrhosis), and 4, liver cirrhosis. Then,
livercirrhosiswassub-classifiedinto three groups: F4A, mildcirrhosis,
definite or probable, 4B, moderate cirrhosis (at least two broad septa),
and 4C, severe cirrhosis (at least one very broad septum or many
minute nodules). The activity grade referred to the degree of
necroinflammatory activity in the lobule and periportal area and was
scored in five grades: A0, no activity, A1, minimal, A2, mild, A3,
moderate, and A4, severe activity. Maximal activity grade was
defined as the higher of the lobular and periportal activity. Steatosis in
the liver specimen was graded on a four-point scale: S0 (insignificant,
,5%), S1 (mild, 5–33%), S2 (moderate, 34–66%), and S3 (severe,
$66% of hepatocytes with fat deposits) [20,21].
Statistical analysis
Patient characteristics are reported as means 6 standard
deviations, medians (ranges), or n (%), as appropriate. Continuous
variables of patients with discordance and those without were
compared with independent t-tests or Mann-Whitney U tests. The
chi-squared or Fisher’s exact test was used for categorical
variables. A discordance was defined as a discordance of at least
two stages between LB and LSM [13]. Cutoff LSM values for
determining discordance were derived from our cohort, which
maximized the sum of sensitivity (Se) and specificity (Sp). Positive
and negative predictive value (PPV and NPV) was also computed.
Spearman’s analysis was used to investigate correlations between
variables. Univariate and subsequent multivariate binary logistic
regression analyses were performed to identify independent factors
related to discordance between LB and LSM. Hazard ratios (HRs)
and corresponding 95% confidence intervals (CIs) are also
indicated. A two-sided P value of ,0.05 was considered
significant. All statistical analyses were performed with the SPSS
software (ver. 12.0; SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study population
After excluding 46 patients according to the predefined
excludion criteria, 150 were included in the final analysis. Baseline
characteristics of the excluded 46 patients including the percentage
of discordance, were not significantly different from those of the
remaining 150 patients (all P.0.05). The baseline characteristics
of study population are listed in Table 1. The mean age, ALT
level, and LSM values were 41.9 years, 74.1 IU/L, and 11.7 kPa,
respectively. The proportions of patients with F2–4, F3–4, and F4
were 84.7% (n=127), 56.0% (n=84), and 45.3% (n=68) and
those of maximal A2–4, A3–4, and A4 were 88.0% (n=132),
40.0% (n=60), and 12.0% (n=18), respectively. Among patients
with cirrhosis (n=68), 8 (11.8%), 44 (64.7%), and 16 (23.5%)
patients showed F4A, F4B, and F4C, respectively.
Liver histology and corresponding LSM values
The median length of LB samples was 17 (range, 15–25) mm. The
fibrosisstageandmaximalactivitygradearesummarizedinTable2.
Most patients (n=126, 84.0%) showed no steatosis (S0) and only 1
(0.1%) patient with F1 fibrosis showed moderate steatosis (S2).
The median and range of LSM values according to maximal
activity grade in each fibrosis stage are listed in Table 2. The
median LSM values increased significantly as fibrosis stage
increased (6.4 kPa for F1, 9.1 kPa for F2, 10.0 kPa for F3, and
12.0 kPa for F4; all P,0.05 between each fibrosis stage;
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fibrosis stage and activity grade increased (Figure S1).
Histological sub-classification of cirrhosis also showed a signifi-
cant increase in the median LSM values (8.5 kPa for F4A, 12.4 kPa
for F4B, and 22.2 kPa for F4C; all P,0.05 among F4A, B, and C;
Figure 1(B)) with no significant difference in ALT levels (median
32.5 (range, 19–70) IU/L for F4A. 42 (range, 12–112) IU/L for
F4B, and 42.5 (range, 25–91) IU/L for F4C; all P.0.05).
Influence of necroinflammatory activity on LSM
according to each fibrosis stage
LSM values between maximal activity grade 1–2 versus 3–4 were
compared in each fibrosis stage (Figure 2). The median LSM
values were not significantly different between maximal activty
grade 1–2 and 3–4 in F1 and F2 fibrosis stage (P=0.676 and 0.139,
respectively), whereas those were significantly higher in maximal
activty grade 3–4 than 1–2 in F3 and F4 fibrosis stage (8.6 vs.
11.3 kPa in F3, P=0.049; 11.9 vs. 19.2 kPa in F4, P=0.009).
The ALT levels in F4 were 40.8615.6 IU/L in the cases with
maximal activity grade 1–2 and 60.7623.3 IU/L in those with
maximal activity grade 3–4, which were significantly different
(P=0.004). In contrast, the ALT levels in F1, F2, and F3 showed
no significant difference between maximal activity grade 1–2
versus 3–4 (50.6638.6 vs. 173.36114.9 IU/L in F1, P=0.121;
72.0651.0 vs. 139.16176.6 IU/L in F2, P=0.224; 35.4623.3 vs.
112.36121.1 IU/L in F3, P=0.146).
Correlations between variables
Among the study variables, the highest correlation was noted
between ALT level and maximal activity grade (correlation
coefficient, 0.497; P,0.001), followed by a correlation between
ALT and age (correlation coefficient, 20.290; P,0.001) and
Table 1. Baseline characteristics.
All patients Patients with non-discordance Patients with discordance P value
(n=150) (n=129, 86.0%) (n=21, 14.0%)
Age, years 41.9614.2 43.1613.4 34.3616.7 0.008*
Male 107 (71.3) 93 (72.1) 14 (66.7) 0.610
BMI, kg/m
2 23.262.8 23.162.7 23.863.5 0.321
Obesity (BMI $30 kg/m
2) 4 (2.7) 2 (1.6) 2 (9.5) 0.094
Alanine aminotransferase, IU/L 74.1698.3 72.96103.1 81.6662.3 0.707
Gamma glutamyltranspeptidase, IU/L 44.5640.3 47.1642.6 32.9626.3 0.295
Platelet count, 10
9/L 188665 183663 219673 0.020*
Liver biopsy
Fibrosis stage
F2–4 127 (84.7) 113 (87.6) 14 (66.7) 0.055
F3–4 84 (56.0) 82 (63.6) 2 (9.5) ,0.001*
F4 68 (45.3) 67 (51.9) 1 (4.8) ,0.001*
Maximal activity
a
A2–4 132 (88.0) 113 (87.6) 19 (90.5) 0.751
A3–4 60 (40.0) 49 (38.0) 11 (52.4) 0.236
A4 18 (12.0) 14 (10.9) 4 (19.0) 0.284
Lobular activity
A2–4 125 (83.3) 106 (82.2) 19 (90.5) 0.530
A3–4 35 (23.3) 26 (20.2) 9 (42.9) 0.047*
A4 1 (0.7) 1 (0.8) 0 0.999
Periportal activity
A2–4 118 (78.7) 100 (77.5) 18 (85.7) 0.568
A3–4 51 (34.0) 43 (33.3) 8 (38.1) 0.804
A4 18 (12.0) 14 (10.9) 4 (19.0) 0.284
Biopsy length, cm 17.962.2 18.062.2 17.162.0 0.125
LSM
LSM value, kPa 11.767.3 11.767.7 11.363.2 0.659
Success rate, % 96.568.0 96.468.3 97.066.8 0.747
IQR/M, kPa 0.1460.09 0.1460.09 0.1360.10 0.830
IQR/M .0.3 10 (6.7) 8 (6.2) 2 (9.5) 0.632
Variables are expressed as mean 6 SD or n (%).
Maximal activity
a grade was defined as the higher one between lobular and periportal activity.
BMI, body mass index; LSM, liver stiffness measurement; kPa, kilopascal; IQR/M, interquartile range/median LSM value.
*P,0.05.
doi:10.1371/journal.pone.0032233.t001
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P=0.038).
Comparison between patients with non-discordance and
those with discordance
Cutoff LSM values from our cohort were 6.0 kPa for $F2 (Se,
90.6%; Sp, 60.9%; PPV, 92.7%; NPV, 53.8%), 7.5 kPa for $F3
(Se, 96.4%; Sp, 57.6%; PPV, 74.3%; NPV, 92.7%), and 9.4 kPa
for F4 (Se, 80.9%; Sp, 73.2%; PPV, 71.4%; NPV, 82.2%), giving a
discordance between LSM and LB in 21 (14.0%) patients
(Table 3). When we compared baseline characteristics between
patients with non-discordance and those with discordance, age,
platelet count, the proportion of F3–4 and F4, and the proportion
of lobular activity grade 3–4 at the time of LB was significantly
different from each other (all P,0.05; Table 1). Although 10
(6.7%) patients with IQR/M.0.3 and one (0.7%) with a success
rate ,60% were identified, IQR/M and success rate were not
selected as significant factors associated with discordance
(P=0.830 and P=0.747, respectively).
Patients with discordance between LB and LSM
When we stratified these 21 patients with discordance into two
groups (LB high group, defined as patients with higher fibrosis
stage based on LB, and LSM high group, defined as those with
higher fibrosis stage based on LSM), only 2 (9.5%) patients were
stratified into the LB high group and 19 (90.5%) into the LSM
high group. The distribution of fibrosis stages based on LB and
LSM is indicated in Table 3.
The mean maximal activity grade and ALT levels of two patients
with discordance in LB high group showed a trend to be lower than
those of the 129 patients with non-discordance (1.560.7 vs. 2.46
0.8, P=0.150 and 25.0612.7 vs.7 2 . 9 6103.1 IU/L, P=0.514,
respectively). The mean maximal activity grade of the 19 patients
with discordance in the LSM high group was higher than the 129
patients with non-discordancewith borderline statistical significance
(2.760.9 vs. 2.460.8, P=0.074), whereas ALT levels only showed a
trend to be higher in the LSM high group than in the 129 patients
with non-discordance (87.6662.5 vs.7 2 . 9 6103.1 IU/L, P=0.547).
Of the two cases in the LB high group, one was classified as F4A
fibrosis stage, with a maximal activity grade of A, and the other
was classified as stage F3, with a maximal activity of A2. The
histology of the former patient with F4A showed a thin fibrous
septa with minimal necroinflammatory activity (Figure 3(A)).
Among the 19 cases in the LSM high group, 7 and 12 cases
showed F1 and F2 fibrosis stage, respectively, and their maximal
Table 2. Liver histology and corresponding LSM values
(n=150).
Fibrosis Maximal activity LSM (kPa)
Stage n (%) Grade n Median (range)
1 23 (15.3) 1 6 5.2 (3.7–8.7)
2 13 5.4 (4.3–15.3)
3 4 7.2 (6.0–8.7)
4- -
2 43 (28.7) 1 - -
2 11 6.8 (4.6–11.0)
3 21 7.8 (5.3–14.3)
4 11 8.8 (5.0–17.1)
3 16 (10.7) 1 2 10.5 (10.0–11.0)
2 7 8.3 (5.7–9.3)
311 3 . 9
4 6 11 (7.9–21.8)
4 68 (45.3) 1 10 9.1 (5.3–14.1)
2 41 13.3 (7.6–34.3)
3 16 18.2 (9.2–48.0)
414 5 . 7
LSM, liver stiffness measurement; kPa, kilopascal.
doi:10.1371/journal.pone.0032233.t002
Figure 1. Box plots of LSM values according to fibrosis stage (A) and sub-classification of cirrhosis (B). Median LSM values increase
significantly as fibrosis stage increases [6.4 kPa for F1 (range 3.7–15.3), 9.1 kPa for F2 (range 4.6–17.1), 10.0 kPa for F3 (range 5.7–21.8), and 12.0 kPa
for F4 (range 5.3–48.0); all P,0.05] and histologic sub-classification of cirrhosis also shows a significant increment in the median LSM values [8.5 kPa
for F4A (range, 5.3–16.2), 12.4 kPa for F4B (range, 7.6–37.8), and 22.2 kPa for F4C (range, 11.2–48.0); all P,0.05].
doi:10.1371/journal.pone.0032233.g001
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One histological example of the LSM high group showed
periportal fibrosis with bridging necrosis (Figure 3(B)).
Independent predictors of discordance
In the multivariate binary logistic regression analysis, only F3–4
and F4 at the time of LB showed independent negative
associations with discordance (P=0.002; HR, 0.073; 95% CI,
0.014–0.390 for F3–4 and P=0.014; HR, 0.067; 95% CI, 0.008–
0.574 for F4). Given that IQR/M was demonstrated to be a
significant predictor of discordance in previous studies [13,15], we
adjusted F3–4 and F4 using IQR/M, although IQR/M was not a
significant discriminating factor of discordance in our univariate
analysis. However, IQR/M was not statistically significant
(P=0.551 with F3–4 and P=0.495 with F4), whereas F3–4 and
F4 at the time of LB remained significant independently
(P=0.002; HR, 0.073, 95% CI, 0.014–0.387 for F3–4 and
P=0.013; HR, 0.065; 95% CI, 0.008–0.559 for F4; Table 4).
Figure 4 showed the discordant rate according to F3–4 and F4.
The estimated odds ratios of discordance, calculated by the chi-
squared test, were 0.060 in patients with F3–4 (P,0.001; 95% CI,
0.013–0.271) and 0.046 in those with F4 (P,0.001; 95% CI,
0.006–0.355).
Discussion
Although LSM is an accurate method that evaluates the degree
of liver fibrosis [5], many extrinsic factors have significant
influences on LSM [6–10]. Additionally, LSM should satisfy the
three intrinsic prerequisites of $10 valid measurements, success
rate $60%, and IQR/M,0.3 to maintain the validity needed to
reflect the real fibrotic state of liver [5]. However, these intrinsic
prerequisites are only the manufacturer’s recommendation.
As a result, several studies have investigated the influence of
IQR/M on the accuracy of LSM [13–15]. Two studies with
chronic hepatitis C (CHC) only [13] or mostly CHC [15] have
proposed optimal cutoff IQR/M values of 0.21 and 0.17,
respectively. In contrast, the other study with CHB did not
identify IQR/M as a significant predictor of accuracy [14].
Indeed, in our study with CHB, IQR/M was not selected as a
significant predictor of discordance. Reasons for this remain
Figure 2. Distribution of LSM values according to fibrosis stage and maxiaml activity grade 1–2 vs. 3–4. The median LSM value was
significantly higher in maxiaml activity grade 3–4 than 1–2 in F3 and F4 fibrosis stage (8.6 [range, 5.7–11.0] vs. 11.3 kPa [range, 7.9–21.8] in F3,
P=0.049; 11.9 [range, 5.3–34.3] vs. 19.2 kPa [range, 9.2–48.0] in F4, P=0.009).
doi:10.1371/journal.pone.0032233.g002
Table 3. Distribution of fibrosis stage based on LB and LSM in
patients with discordance (n=21).
LB high group
a LSM high group
b
(n=2, 9.5%) (n=19, 90.5%)
Fibrosis stage
F1 – 7
F2 – 12
F3 1 –
F4 1 –
LSM value, kPa
F1 (,6.0 kPa) 2 –
F2 ($6.0 kPa) 0 –
F3 ($7.5 kPa) – 4
F4 ($9.4 kPa) – 15
LB, liver biopsy; LSM, liver stiffness measurement; kPa, kilopascal.
A discordance was defined as a discordance of at least two stages between LB
and LSM.
LB high group
a was defined as patients with higher fibrosis stage based on LB.
LSM high group
b was defined as patients with higher fibrosis stage based on
LSM.
doi:10.1371/journal.pone.0032233.t003
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ours (both mean IQR/M 0.14) was much lower than in CHC
studies (0.23 [13] and 0.16 [15]) indicating that LSM performed
more accurately. We believe that IQR/M may not be a sensitive
marker to predict discordance in CHB because of the influence of
inhomogeneous histological features or necroinflammation that
overwhelm the influence of IQR/M on LSM [22]. Consistent with
the literature [13–15], success rate was not a significant predictor
of discordance in our study, which might mean that ‘high quality,’
reflected by lower IQR/M, does matter for the accurate
interpretation of LSM, rather than a ‘high percentage’ of
successful shots.
In addition to IQR/M, fibrosis stage (F0–2 vs. F3–4) and
elevated ALT (.1.5–26 ULN) were proposed as significant
extrinsic predictors of discordance [13–15]. However, controversy
remains regarding fibrosis stage. Lucidarme et al. [13] concluded
that advanced fibrosis (F3–4) was correlated with discordance,
while Kim et al. [14] and Myers et al. [15] proposed minimal
fibrosis (F0–2) as a significant predictor of discordance between LB
and LSM. In our study, F3–4 and F4 showed a negative
correlation with discordance. The significantly lower rate of
discordance in F4 may be explained by an unlimited upper cutoff
LSM value for cirrhosis until 75 kPa in this study design.
Accordingly, F3–4, which included a high proportion of F4
(80.9%), also showed a negative correlation with discordance.
From these results, we suggest that a different predictor of
discordance may be produced according to a different distribution
of F4. Furthermore, this hypothesis may explain why ALT level
was not selected as a significant predictor of discordance in our
study with a higher prevalence of F3–4 (56.0%) than in a previous
study (20.3%) that proposed ALT as a significant predictor of
discordance [15]. This confounding effect of elevated ALT may
have been attenuated in our study due to a higher proportion of
F4, which is free to misdiagnosis due to LSM overestimation by
elevated ALT, despite similar ALT levels between the two studies
[mean 61 IU/L [15] vs. 74 IU/L in the present study].
Thus, the potentially masked influence of necroinflammation in
F4, the consistent reports on the overestimating effects of elevated
ALT, and the significant correlation between lobular activity grade
3–4 and discordance in our univariate analysis prompted us to
Figure 3. Histology of LB high group (A) and LSM high group (B) (Masson trichrome, original magnification6100). (A) a patient in LB
high group (F4A, maximal activity grade of A1, and ALT level of 34 IU/L) showed a thin fibrous septa and minimal necroinflammatory activity. (B) a
patient in LSM high group (F2, maximal activity grade of A4, and ALT level of 168 IU/L) showed periportal fibrosis with bridging necrosis.
doi:10.1371/journal.pone.0032233.g003
Table 4. Independent predictors of discordance between LSM and LB.
Univariate Multivariate
P value
P value
(with F3–4)
P value
(with F4) Hazard ratio 95% confidence interval
Age 0.008* 0.906 0.640 - -
Platelet count 0.020* 0.769 0.574 - -
A3–4 (lobular) 0.047* 0.658 0.543 - -
F3–4 ,0.001* 0.002* - 0.073 0.014–0.390
F4 ,0.001* - 0.014* 0.067 0.008–0.574
IQR/M adjusted
Age 0.008* 0.851 0.596 - -
Platelet count 0.020* 0.710 0.520 - -
A3–4 (lobular) 0.047* 0.613 0.512 - -
IQR/M 0.830 0.551 0.495 - -
F3–4 ,0.001* 0.002* - 0.073 0.014–0.387
F4 ,0.001* - 0.013* 0.065 0.008–0.559
LSM, liver stiffness measurement; LB, liver biopsy; IQR/M, interquartile range/median value.
*P,0.05.
doi:10.1371/journal.pone.0032233.t004
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on LSM. The maximal activity grade 3–4 significantly influenced
LSM values in F3 and F4, but not in F1 or F2, which may be
explained in several ways. First, the mean ALT level was not
significantly different in A1–2 versus A3–4 in F1 and F2 in our
cohort. Thus, the ALT effect could not be revealed. Second,
extrinsic factors, such as liver congestion [7] and respiration [23]
resulting in a change of portal flow concurrent with necroin-
flammation, may have influenced the performance of LSM when
liver fibrosis was insufficient (#F2) to be detected by LSM. These
combined effects of several confounders might have concealed the
effects of necroinflammation on LSM, consistent with a recent
meta-analysis on LSM reporting the relatively lower performance
of LSM to predict significant fibrosis ($F2) [24].
Most patients (90.5%) with discordance were stratified into the
LSM high group, indicating that LSM values were subject to
overestimation due to necroinflammation or high ALT. Although
statistical significance for necroinflammation and high ALT was not
seen when we compared patients with non-discordance with those
in the LSM high group, the clinical implications should be further
investigated in future studies, considering the borderline statistical
significanceof highALT(P=0.074) and the small sample sizeof the
LB high group. Indeed, clinical variables, such as ALT level, which
showed the best correlation with necroinflammatory activity in our
study, are needed to predict the discordance ‘before LB,’ because
histological variables, such as fibrosis stage or activity grade, which
are only available ‘after LB’ are not helpful for the prediction of the
discordance between LB and LSM. Indeed, the concept of
excluding subjects with high ALT to enhance the accuracy of
LSM has already been proposed [17,25]. Although ALT was not a
significant predictor, the optimal cutoff ALT level to predict
discordance was 55 IU/L (data not shown). Furthermore, the mean
ALTs of maximal activity grade 3–4 in F3 and F4 that raised LSM
values significantly were 60.7 and 112.3 IU/L, respectively.
Because the ALT cutoff seemed to be around 1.5–36 ULN in
our study and 1.5–26ULN in previous ones [14,15,26], ALT level
#36ULN may be optimal to enhance LSM performance.
Interestingly, LSM values showed a significant stepwise incre-
ment according to F4A, B, and C without a significant difference in
ALT levels in our study, indicating that LSM can further stratify
patients with cirrhosis. Thus, mild liver cirrhosis (F4A) might have a
higher chance of being underestimated by LSM than moderate or
severe cirrhosis (F4B or F4C), especially when necroinflammatory
activity or ALT level is low. This could be a reason why one patient
with F4A and A1 activity grade belonged to the LB high group.
Although the histological sub-classification of cirrhosis is gaining
clinical relevance [27], stratification of cirrhosis according to the
Laennec system or LSM should be further validated via long-term
follow-up studies using solid clinical end-points, such as liver-related
death or development of hepatocellular carcinoma.
In conclusion, advanced fibrosis stage (F3–4) or cirrhosis (F4)
showed a negative correlation with discordance between LB and
LSM in patients with CHB, and maximal activity grade 3–4
significantly influenced LSM values in F3–4 and F4. Thus, future
studies should investigate how to control for the clinical marker of
ALT, which may bridge histological information to enhance the
accuracy of LSM.
Supporting Information
Figure S1 The median LSM values according to fibrosis
stage and activity grade [maximal (A), lobular (B), and
periportal activity grade (C)]. The median LSM values
tended to increase as fibrosis stage and activity grade increase.
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